Praxis Precision Medicines to Participate in September Investor Conferences
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has announced its participation in three major investor conferences in September 2025:
- Baird Global Healthcare Conference - Corporate presentation on September 9th at 9:00 AM EDT
- H.C. Wainwright Global Investment Conference - Fireside chat on September 10th at 8:30 AM EDT
- TD Cowen Novel Mechanisms Summit - Virtual presentation on September 18th at 3:00 PM EDT
One-on-one meetings will be available at all events, and webcasted presentations will be accessible through the company's website for 90 days.
Praxis Precision Medicines (NASDAQ: PRAX), azienda biofarmaceutica in fase clinica specializzata in disturbi del sistema nervoso centrale, ha comunicato la sua partecipazione a tre importanti conferenze per investitori a settembre 2025:
- Baird Global Healthcare Conference - Presentazione aziendale il 9 settembre alle 9:00 EDT
- H.C. Wainwright Global Investment Conference - Conversazione informale (fireside chat) il 10 settembre alle 8:30 EDT
- TD Cowen Novel Mechanisms Summit - Presentazione virtuale il 18 settembre alle 15:00 EDT
All'evento saranno disponibili incontri individuali e le presentazioni trasmesse in webcast saranno accessibili sul sito web della societ脿 per 90 giorni.
Praxis Precision Medicines (NASDAQ: PRAX), una compa帽铆a biofarmac茅utica en fase cl铆nica centrada en trastornos del SNC, ha anunciado su participaci贸n en tres importantes conferencias de inversores en septiembre de 2025:
- Baird Global Healthcare Conference - Presentaci贸n corporativa el 9 de septiembre a las 9:00 EDT
- H.C. Wainwright Global Investment Conference - Conversaci贸n informal (fireside chat) el 10 de septiembre a las 8:30 EDT
- TD Cowen Novel Mechanisms Summit - Presentaci贸n virtual el 18 de septiembre a las 15:00 EDT
Habr谩 reuniones individuales en todos los eventos y las presentaciones en webcast estar谩n disponibles en el sitio web de la compa帽铆a durante 90 d铆as.
Praxis Precision Medicines (NASDAQ: PRAX)電� 欷戩稊鞁犼步瓿�(CNS) 歆堩櫂鞚� 欷戩嫭鞙茧 鞐瓣惮頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿�, 2025雲� 9鞗旍棎 鞐措Μ電� 靹� 瓿踌潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟:
- Baird Global Healthcare Conference - 9鞗� 9鞚� 鞓れ爠 9:00 EDT鞐� 旮办梾 氚滍憸
- H.C. Wainwright Global Investment Conference - 9鞗� 10鞚� 鞓れ爠 8:30 EDT鞐� 韺岇澊鞏挫偓鞚措摐 毂勴姼
- TD Cowen Novel Mechanisms Summit - 9鞗� 18鞚� 鞓ろ泟 3:00 EDT鞐� 鞓澕鞚� 氚滍憸
氇摖 頄夓偓鞐愳劀 鞚茧寑鞚� 氙疙寘鞚� 臧�電ロ晿氅�, 鞗轨簮鞀ろ姼霅� 氚滍憸電� 須岇偓 鞗轨偓鞚错姼鞐愳劀 90鞚缄皠 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Praxis Precision Medicines (NASDAQ: PRAX), soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les troubles du syst猫me nerveux central, a annonc茅 sa participation 脿 trois grandes conf茅rences investisseurs en septembre 2025 :
- Baird Global Healthcare Conference - Pr茅sentation institutionnelle le 9 septembre 脿 9h00 EDT
- H.C. Wainwright Global Investment Conference - Entretien informel (fireside chat) le 10 septembre 脿 8h30 EDT
- TD Cowen Novel Mechanisms Summit - Pr茅sentation virtuelle le 18 septembre 脿 15h00 EDT
Des r茅unions individuelles seront propos茅es lors de chaque 茅v茅nement et les pr茅sentations diffus茅es en webcast seront accessibles sur le site web de la soci茅t茅 pendant 90 jours.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in klinischer Phase mit Fokus auf ZNS-Erkrankungen, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 angek眉ndigt:
- Baird Global Healthcare Conference - Unternehmenspr盲sentation am 9. September um 9:00 Uhr EDT
- H.C. Wainwright Global Investment Conference - Fireside-Chat am 10. September um 8:30 Uhr EDT
- TD Cowen Novel Mechanisms Summit - Virtuelle Pr盲sentation am 18. September um 15:00 Uhr EDT
Einzelgespr盲che sind bei allen Veranstaltungen m枚glich, und die per Webcast 眉bertragenen Pr盲sentationen werden f眉r 90 Tage auf der Website des Unternehmens verf眉gbar sein.
- None.
- None.
BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that Praxis鈥� management will be attending and presenting in three upcoming investor conferences:
- Baird 2025 Global Healthcare Conference: a corporate presentation will take place on Tuesday, September 9th at 9:00-9:35am EDT at the InterContinental New York Barclay.
- H.C. Wainwright 27th Annual Global Investment Conference: a fireside chat will be held on Wednesday, September 10th at 8:30am EDT at the Lotte New York Palace Hotel in New York City. A live webcast of the fireside chat will be available through this .
- TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit: a corporate presentation will take place virtually on Thursday, September 18th at 3:00-3:30pm EDT.
The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.
A replay of the webcasted event will also be available through the 鈥溾�� page under the 鈥溾�� section of the company鈥檚 website for 90 days.
About Praxis鈥�
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum鈩�, and antisense oligonucleotide (ASO) platform, Solidus鈩�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit聽聽and follow us on聽,听,听听补苍诲听.
Investor Contact:聽 Praxis Precision Medicines聽 [email protected]聽 857-702-9452聽 聽 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576
FAQ
When is Praxis Precision Medicines (PRAX) presenting at the Baird Global Healthcare Conference 2025?
How can investors access Praxis Precision Medicines' (PRAX) conference presentations?
What types of meetings is Praxis Precision Medicines (PRAX) offering at the September 2025 conferences?
What is Praxis Precision Medicines' (PRAX) main focus as a company?
